Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.64 |
| ▸ | CNR1 | P21554 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037472 | 0.99 | CNR2 (0.63) | CNR2CNR1KDM4EIDO1HTT | |
| SCHEMBL6870502 | 0.85 | CNR1 (0.71) | CNR2CNR1 | |
| SCHEMBL548607 | 0.84 | CNR2 (0.70) | CNR2CNR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9340471 | 0.84 | CNR2 (0.70) | CNR2CNR1KDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2035939 | 0.83 | CNR2 (0.68) | CNR2CNR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12643110 | 0.83 | CNR2 (0.69) | CNR2CNR1KDM4EALDH1A1PLK1 | |
| Hydrochloric Acid SCHEMBL2041733 | 0.82 | CNR2 (0.67) | CNR2CNR1KDM4EALDH1A1PLK1 | |
| SCHEMBL2038252 | 0.80 | CNR1 (0.50) | CNR2CNR1KDM4EIDO1HTT | |
| SCHEMBL2186845 | 0.78 | KDM4E (0.74) | CNR2CNR1KDM4EIDO1HTT | |
| SCHEMBL29051451 | 0.78 | KDM4E (0.74) | CNR2KDM4EIDO1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 113/4885CNR1 160/4885KDM4E 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.